Remove Atrial Fibrillation Remove Research Remove Risk Factors
article thumbnail

3 Powerful Strategies: Combatting Cardiometabolic Risk Factors for Black Americans 

Cardiometabolic Health Congress

When we explore the three traditional cardiometabolic risk factors (obesity, type 2 diabetes, and dyslipidemia) and the emerging cardiometabolic risk factor of non-alcoholic fatty liver disease, we unearth a complex interplay of societal, biological, genetic, and environmental factors.

article thumbnail

Biosense Webster Submits Application to U.S. FDA Seeking Approval of the VARIPULSE Platform for the Treatment of Paroxysmal Atrial Fibrillation

DAIC

2,3 Approximately 1 in 4 adults over the age of 40 are at risk for developing AFib. 6 Learn more about Biosense Webster's PFA research and clinical evidence here. Global epidemiology of atrial fibrillation: An increasing epidemic and public health challenge. Epidemiology of Atrial Fibrillation in the 21st Century.

article thumbnail

Late-breaking Clinical Trial Results from FARADISE, adMIRE Study and Advent Trial at Heart Rhythm 2024 Highlight Pulsed Field Ablation Developments for Atrial Fibrillation Treatment

DAIC

During its Annual Conference, HRS 2024, the Heart Rhythm Society (HRS) announced findings from three new studies demonstrating the safety and efficacy of pulsed field ablation (PFA), a nonthermal ablation treatment for patients with atrial fibrillation (AF). See full findings from the FARADISE, admIRE Study, and Advent Trial here.

article thumbnail

Medtronic Creates History with FDA Approval of its Novel PulseSelect Pulsed Field Ablation System to Treat Atrial Fibrillation

DAIC

The PulseSelect PFA system, together with the CE Marked Affera mapping and ablation system and our strong Cryo platform, enables us to provide a broad portfolio of solutions to clinicians and their patients, all developed with years of research and supported by compelling scientific evidence." Roth GA, Mensah GA, Johnson CO et al.

article thumbnail

Atrial Fibrillation Ablation in Congenital Heart Disease: Therapeutic Challenges and Future Perspectives

Journal of the American Heart Association

The increasing prevalence of atrial fibrillation (AF) in adults with congenital heart disease raises significant questions regarding its management. Finally, any remaining gaps in knowledge and potential areas of future research are highlighted. Journal of the American Heart Association, Ahead of Print.

article thumbnail

2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines

Circulation

Additional relevant studies, published through November 2022, during the guideline writing process, were also considered by the writing committee and added to the evidence tables, where appropriate.StructureAtrial fibrillation is the most sustained common arrhythmia, and its incidence and prevalence are increasing in the United States and globally.

article thumbnail

Lifestyle & risk factor changes improved AFib symptoms, not burden, over standard care

American Heart News - Heart News

Research Highlights: A clinical trial with adults who have atrial fibrillation (AFib) and an implanted heart device found similar improvements to the amount of time they experienced arrhythmia regardless of whether they received standard care.

AFIB 59